


Ordering information

Description	Product Number
Instruments	
HYDRASYS 2 Scan Focusing	1202
Accessories	
HYDRASHIFT 2/4 Accessories (Applicator carrier specific for HYDRASHIFT)	1251
Reagents	
HYDRASHIFT 2/4 isatuximab (40 tests)	4642
HYDRAGEL 2 IF Acid violet	4302
HYDRAGEL 4 IF Acid violet	4304
Antisera and Fixative for immunofixation IF	4315
HYDRAGEL 2 IF Acid violet	4802
HYDRAGEL 4 IF Acid violet	4804
Antisera and Fixative for immunofixation IF	4815
Controls/Calibrators	
isatuximab control	4764
Consumables (optional)	
Applicators Green HYDRASHIFT (10 individual Applicators green)	4195

©2020 sebia - Non-contractual illustration - 11/2020 - Ref.: HSB1EN
Sebia reserves the right to modify at any time and without notice the information contained in this document intended for healthcare professionals.
This document contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.

HYDRASHIFT isatuximab



HYDRASHIFT
avoids isatuximab
interference on
IMMUNOFIXATION

sebia
RCS Evry 672 041 902
Parc technologique Léonard de Vinci
27 rue Léonard de Vinci
CP 8010 Lisses - 91008 Evry cedex
FRANCE
Tel. : +33 1 69 89 80 80
E-mail : sebia@sebia.com
www.sebia.com


Benelux - Tel.: +32 2 702 64 64 (BE) - Tel.: +31 20 610 8099 (NL) - E-mail: sebia.benelux@sebia.com • Brasil - Tel.: +55 11 3849 0148 - E-mail: sebia@sebia.com.br • Canada - E-mail: canada@sebia.com
China - Tel.: +86 (21) 6360 1436 - Fax: +86 (21) 6361 2011 - E-mail: china@sebia.com • Dubai - Tel.: +971 (0)4 878 6977 • Germany - Tel.: +49 (0) 661 33081 - Fax: +49 (0) 661 31881 - E-mail: sebia@sebia.de
India - Tel.: +91 124 4262100 - E-mail: sebiaindia@sebia.com • Italy - Tel.: +39 055 24851 - Fax: +39 055 0982083 - E-mail: info@sebia.it • Portugal - Tel.: +351 211 224 653 -
Fax: +351 211 305 079 - E-mail: portugal@sebia.com Spain - Tel.: +34 93 208 15 52- Fax: +34 93 458 55 86 - E-mail: sebia@sebia.es • Swiss - Tel.: +41 44 787 88 10 - Fax: +41 44 787 88 19 -
E-mail: contact.ch@sebia.com UK - Tel.: +44 (01276) 600636 - Fax: +44 (01276) 38827- E-mail: sales@sebia.co.uk • U.S.A. - Tel.: +1 (770) 446-3707 - Fax: +1 (770) 446-8511 - E-mail: info@sebia-usa.com

in collaboration with
SANOFI

sebia


What is SARCLISA®?

- SARCLISA® (isatuximab-irfc) is a human monoclonal antibody (mAB) targeting CD38 used in Multiple Myeloma (MM) treatment regimens.
- Treatments with mAB can affect the interpretation on immunofixation (IF) tests.
- IF is one of the tests referenced in the IMWG guidelines to assess the complete response to treatment in a patient with MM.




HYDRASHIFT avoids isatuximab interference on IF

- HYDRASHIFT isatuximab is a unique "SHIFT" technology to avoid isatuximab interference using HYDRAGEL 2/4 IF on HYDRASYS 2 platforms.
- Easy to implement: no sample pre-treatment, same IF protocol.



* Contact your Sebia representative for other regulatory approvals

Clinical Case #1



Clinical Case #2

